<SEC-DOCUMENT>0001104659-23-011184.txt : 20230206
<SEC-HEADER>0001104659-23-011184.hdr.sgml : 20230206
<ACCEPTANCE-DATETIME>20230206161454
ACCESSION NUMBER:		0001104659-23-011184
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		16
CONFORMED PERIOD OF REPORT:	20230206
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20230206
DATE AS OF CHANGE:		20230206

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			COLLEGIUM PHARMACEUTICAL, INC
		CENTRAL INDEX KEY:			0001267565
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			VA
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37372
		FILM NUMBER:		23590821

	BUSINESS ADDRESS:	
		STREET 1:		100 TECHNOLOGY CENTER DRIVE
		CITY:			STOUGHTON
		STATE:			MA
		ZIP:			02072
		BUSINESS PHONE:		781-713-3699

	MAIL ADDRESS:	
		STREET 1:		100 TECHNOLOGY CENTER DRIVE
		CITY:			STOUGHTON
		STATE:			MA
		ZIP:			02072

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	COLLEGIUM PHARMACEUTICAL INC
		DATE OF NAME CHANGE:	20031020
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>tm235588d1_8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2021q4" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:us-roles="http://fasb.org/us-roles/2021-01-31" xmlns:country="http://xbrl.sec.gov/country/2021" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:coll="http://collegiumpharma.com/20230206">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html" />
</head>
<!-- Field: Set; Name: xdx; ID: xdx_02A_US%2DGAAP%2D2021 -->
<!-- Field: Set; Name: xdx; ID: xdx_036_coll_collegiumpharma.com_20230206 -->
<!-- Field: Set; Name: xdx; ID: xdx_040_20230206_20230206 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DEntityCentralIndexKey_0001267565 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="From2023-02-06to2023-02-06" name="dei:EntityCentralIndexKey">0001267565</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2023-02-06to2023-02-06" name="dei:AmendmentFlag">false</ix:nonNumeric>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="coll-20230206.xsd" xlink:type="simple" />
  </ix:references>
 <ix:resources>
    <xbrli:context id="From2023-02-06to2023-02-06">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001267565</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-02-06</xbrli:startDate>
        <xbrli:endDate>2023-02-06</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
  </ix:resources>
 </ix:header>
</div>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Rule-Page --><div style="margin-top: 0; margin-bottom: 0; width: 100%"><div style="border-top: Black 2pt solid; border-bottom: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>UNITED STATES</b></p>

<p style="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SECURITIES AND EXCHANGE COMMISSION</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Washington, D.C. 20549</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>FORM&#160;<span id="xdx_90B_edei--DocumentType_c20230206__20230206_z7Tpi2Iy7tN1"><ix:nonNumeric contextRef="From2023-02-06to2023-02-06" name="dei:DocumentType">8-K</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>CURRENT REPORT</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Pursuant to Section&#160;13 or 15(d)</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>of the Securities Exchange Act of 1934</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Date of Report (Date of earliest event reported):
<span id="xdx_901_edei--DocumentPeriodEndDate_c20230206__20230206_z5ZrEz6rcGyk"><ix:nonNumeric contextRef="From2023-02-06to2023-02-06" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate">February  6, 2023</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 24pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="xdx_900_edei--EntityRegistrantName_c20230206__20230206_znjvn5BDrtL6"><ix:nonNumeric contextRef="From2023-02-06to2023-02-06" name="dei:EntityRegistrantName">COLLEGIUM PHARMACEUTICAL, INC.</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(Exact name of registrant as specified in its
charter)</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="vertical-align: top; width: 32%; text-align: center"><b><span id="xdx_908_edei--EntityIncorporationStateCountryCode_c20230206__20230206_zIk3mr2TYlnh"><ix:nonNumeric contextRef="From2023-02-06to2023-02-06" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode">Virginia</ix:nonNumeric></span></b></td>
    <td style="vertical-align: bottom; width: 2%">&#160;</td>
    <td style="vertical-align: top; width: 32%; text-align: center"><b><span id="xdx_90B_edei--EntityFileNumber_c20230206__20230206_zVwIILl7xBDf"><ix:nonNumeric contextRef="From2023-02-06to2023-02-06" name="dei:EntityFileNumber">001-37372</ix:nonNumeric></span></b></td>
    <td style="vertical-align: bottom; width: 2%">&#160;</td>
    <td style="vertical-align: top; width: 32%; text-align: center"><b><span id="xdx_905_edei--EntityTaxIdentificationNumber_c20230206__20230206_za2Hm3SbpIUe"><ix:nonNumeric contextRef="From2023-02-06to2023-02-06" name="dei:EntityTaxIdentificationNumber">03-0416362</ix:nonNumeric></span></b></td></tr>
  <tr>
    <td style="vertical-align: top; text-align: center"><b>(state or other jurisdiction</b><br />
<b>of incorporation)</b>&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td>
    <td style="vertical-align: top; text-align: center"><b>(Commission<br />
File Number)</b>&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td>
    <td style="vertical-align: top; text-align: center"><b>(I.R.S. Employer</b><br />
<b>Identification No.)</b>&#160;</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="width: 50%">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="xdx_906_edei--EntityAddressAddressLine1_c20230206__20230206_zzMD16Hfyela"><ix:nonNumeric contextRef="From2023-02-06to2023-02-06" name="dei:EntityAddressAddressLine1">100 Technology Center Drive</ix:nonNumeric></span></b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="xdx_90A_edei--EntityAddressAddressLine2_c20230206__20230206_zZfFKz7z6u75"><ix:nonNumeric contextRef="From2023-02-06to2023-02-06" name="dei:EntityAddressAddressLine2">Suite 300</ix:nonNumeric></span></b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="xdx_908_edei--EntityAddressCityOrTown_c20230206__20230206_zmKjwykN2Dck"><ix:nonNumeric contextRef="From2023-02-06to2023-02-06" name="dei:EntityAddressCityOrTown">Stoughton</ix:nonNumeric></span>, <span id="xdx_908_edei--EntityAddressStateOrProvince_c20230206__20230206_z4yaHCBPOVp6"><ix:nonNumeric contextRef="From2023-02-06to2023-02-06" name="dei:EntityAddressStateOrProvince">MA</ix:nonNumeric></span></b></p></td>
    <td style="width: 50%; text-align: center"><b><span id="xdx_906_edei--EntityAddressPostalZipCode_c20230206__20230206_zCJvppN5avIi"><ix:nonNumeric contextRef="From2023-02-06to2023-02-06" name="dei:EntityAddressPostalZipCode">02072</ix:nonNumeric></span></b></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><b>(Address of principal executive offices)</b></td>
    <td style="text-align: center"><b>(Zip Code)</b></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Registrant&#8217;s telephone number, including
area code: (<span id="xdx_908_edei--CityAreaCode_c20230206__20230206_zo5EiajhVKW6"><ix:nonNumeric contextRef="From2023-02-06to2023-02-06" name="dei:CityAreaCode">781</ix:nonNumeric></span>) <span id="xdx_90F_edei--LocalPhoneNumber_c20230206__20230206_zCof8nvGf61h"><ix:nonNumeric contextRef="From2023-02-06to2023-02-06" name="dei:LocalPhoneNumber">713-3699</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(Former name or former address, if changed since
last report)</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Securities registered pursuant to Section&#160;12(b)&#160;of the Act:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 33%; text-align: center"><b>Title of each class</b></td>
    <td style="width: 34%; text-align: center"><b>Trading<br />
Symbol(s)</b></td>
    <td style="width: 33%; text-align: center"><b>Name of each exchange on which registered</b></td></tr>
  <tr style="vertical-align: top">
    <td><span id="xdx_902_edei--Security12bTitle_c20230206__20230206_z6NgI98pvwM8"><ix:nonNumeric contextRef="From2023-02-06to2023-02-06" name="dei:Security12bTitle">Common stock, par value $0.001 per share</ix:nonNumeric></span></td>
    <td style="text-align: center"><span id="xdx_909_edei--TradingSymbol_c20230206__20230206_zv13biLPsMpk"><ix:nonNumeric contextRef="From2023-02-06to2023-02-06" name="dei:TradingSymbol">COLL</ix:nonNumeric></span></td>
    <td style="text-align: center"><span id="xdx_904_edei--SecurityExchangeName_c20230206__20230206_zqXDnLgJDZGg"><ix:nonNumeric contextRef="From2023-02-06to2023-02-06" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName">The NASDAQ Global Select Market</ix:nonNumeric></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Check the appropriate box below if the Form&#160;8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2.
below):</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 29px"><span style="font-family: Wingdings"><span id="xdx_907_edei--WrittenCommunications_c20230206__20230206_zoEkjCJFwt9h"><ix:nonNumeric contextRef="From2023-02-06to2023-02-06" format="ixt:booleanfalse" name="dei:WrittenCommunications">&#168;</ix:nonNumeric></span></span>&#160;</td>
    <td>Written communications pursuant to Rule&#160;425 under the Securities Act (17 CFR 230.425) </td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 29px"><span style="font-family: Wingdings"><span id="xdx_90B_edei--SolicitingMaterial_c20230206__20230206_zpz921QzNdB4"><ix:nonNumeric contextRef="From2023-02-06to2023-02-06" format="ixt:booleanfalse" name="dei:SolicitingMaterial">&#168;</ix:nonNumeric></span></span>&#160;</td>
    <td>Soliciting material pursuant to Rule&#160;14a-12 under the Exchange Act (17 CFR 240.14a-12) </td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 29px"><span style="font-family: Wingdings"><span id="xdx_908_edei--PreCommencementTenderOffer_c20230206__20230206_zqPxzEGq3DT"><ix:nonNumeric contextRef="From2023-02-06to2023-02-06" format="ixt:booleanfalse" name="dei:PreCommencementTenderOffer">&#168;</ix:nonNumeric></span></span>&#160;</td>
    <td>Pre-commencement communications pursuant to Rule&#160;14d-2(b)&#160;under the Exchange Act (17 CFR 240.14d-2(b)) </td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 29px"><span style="font-family: Wingdings"><span id="xdx_905_edei--PreCommencementIssuerTenderOffer_c20230206__20230206_zR8vnGi0h7"><ix:nonNumeric contextRef="From2023-02-06to2023-02-06" format="ixt:booleanfalse" name="dei:PreCommencementIssuerTenderOffer">&#168;</ix:nonNumeric></span></span>&#160;</td>
    <td>Pre-commencement communications pursuant to Rule&#160;13e-4(c)&#160;under the Exchange Act (17 CFR 240.13e-4(c)) </td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicated by check mark whether the registrant is an emerging growth
company as defined in Rule&#160;405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule&#160;12b-2 of the Securities
Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Emerging growth company <span style="font-family: Wingdings"><span id="xdx_901_edei--EntityEmergingGrowthCompany_c20230206__20230206_z0y19Gvx9Dik"><ix:nonNumeric contextRef="From2023-02-06to2023-02-06" format="ixt:booleanfalse" name="dei:EntityEmergingGrowthCompany">&#168;</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If an emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant
to Section&#160;13(a)&#160;of the Exchange Act. <span style="font-family: Wingdings">&#168;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Rule-Page --><div style="margin-top: 0; margin-bottom: 0; width: 100%"><div style="border-top: Black 1pt solid; border-bottom: Black 2pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0"></td><td style="width: 1in"><b>Item 2.02</b></td><td><b>Results of Operations and Financial Condition. </b></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The information set forth under Item 7.01 regarding the press release
announcing certain preliminary unaudited financial information is incorporated by reference into this Item 2.02.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>The information contained in this Item 2.02 is being furnished and
shall not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange
Act&#8221;), or otherwise subject to the liabilities of that Section. The information contained in this Item 2.02 shall not be incorporated
by reference into any registration statement or other document pursuant to the Securities Act of 1933, as amended (the &#8220;Securities
Act&#8221;), or the Exchange Act, unless it is specifically incorporated by reference therein.</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0"></td><td style="width: 1in"><b>Item 7.01</b></td><td><b>Regulation FD Disclosure.</b></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On February 6, 2023, Collegium Pharmaceutical, Inc. (the &#8220;Company&#8221;)
issued a press release announcing certain preliminary unaudited financial information for its fiscal quarter and fiscal year ended December
31, 2022. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference
into this Item 7.01.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>The information contained in this Item 7.01 and the attached Exhibit
99.1 is being furnished and shall not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Exchange Act, or otherwise subject
to the liabilities of that Section. The information contained in this Item 7.01 and the attached Exhibit 99.1 shall not be incorporated
by reference into any registration statement or other document pursuant to the Securities Act or the Exchange Act, unless it is specifically
incorporated by reference therein.</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0"></td><td style="width: 1in"><span style="background-color: white"><b>Item 8.01</b></span></td><td><span style="background-color: white"><b>Other Information.</b></span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">On February 6, 2023, the Company issued a
press release relating to its proposed offering of Convertible Senior Notes due 2029 (the &#8220;Notes&#8221;) to persons reasonably believed
to be qualified institutional buyers pursuant to Rule 144A under the Securities Act. A copy of the press release is attached as Exhibit
99.2 to this Current Report on Form 8-K and is incorporated by reference into this Item 8.01.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">This Current Report on Form 8-K, including
the exhibits attached hereto, does not constitute an offer to sell, or the solicitation of an offer to buy, the Notes or the shares of
the Company&#8217;s common stock, if any, issuable upon conversion of the Notes.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0"></td><td style="width: 1in"><b>Item 9.01</b></td><td><b>Financial Statements and Exhibits.</b></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(d)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Exhibits</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="width: 13%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exhibit</b></span></td>
    <td style="width: 2%">&#160;</td>
    <td style="white-space: nowrap; vertical-align: bottom; width: 85%">&#160;</td></tr>
  <tr>
    <td style="border-bottom: black 1pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>No.</b></span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Description</b></span></td></tr>
  <tr>
    <td style="padding-bottom: 8pt"><a href="tm235588d1_ex99-1.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.1</span></a></td>
    <td style="padding-bottom: 8pt">&#160;</td>
    <td style="white-space: nowrap; vertical-align: bottom; padding-bottom: 8pt"><a href="tm235588d1_ex99-1.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Press Release, dated February 6, 2023</span></a></td></tr>
  <tr>
    <td style="padding-bottom: 8pt"><a href="tm235588d1_ex99-2.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.2</span></a></td>
    <td style="padding-bottom: 8pt">&#160;</td>
    <td style="white-space: nowrap; vertical-align: bottom; padding-bottom: 8pt"><a href="tm235588d1_ex99-2.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Press Release, dated February 6, 2023</span></a></td></tr>
  <tr>
    <td style="padding-bottom: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #212529">104</span></td>
    <td style="padding-bottom: 8pt">&#160;</td>
    <td style="padding-bottom: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #212529">Cover Page Interactive Data File (embedded within the Inline XBRL document)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 3 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SIGNATURES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td colspan="2"><b>Collegium Pharmaceutical,&#160;Inc.</b></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td colspan="2">&#160;</td></tr>
  <tr>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr>
    <td style="vertical-align: top; width: 50%; padding-bottom: 1.25pt">&#160;</td>
    <td style="vertical-align: top; width: 3%">By:</td>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom; width: 47%">/s/ Colleen Tupper</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>Colleen Tupper</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>Executive Vice President and Chief Financial Officer</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Dated: February 6, 2023</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 4; Options: Last -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

</body>
</html>
<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!-- eJxFjdEKgkAQRb/Afxj2Ocw168HHpCKyCInodckxlnRHZjfLT+ov25RoGBiGe8+9QkzEhta6RobLssjhhE1bK4dQYIWM5orekW13Kfhb4E1bx8q44f2BGXkGPTMP5eLqhcHaaYtlCpGcRrNpPAMZp0kCx70IvnpGptIlGqdVDcqUcGRqWaNT3I8JJ/UiQ00/VJ2RrSaTggyjUX5DHMkYDtSpJ/HdQp5nIpgME4gN06P91jysowZWNTa+y47of4MPGBVJSQ== -->
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>tm235588d1_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="text-align: right; margin: 0"><B>Exhibit 99.1</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0"><IMG SRC="tm235588d1_ex99-1img001.jpg" ALT="">&nbsp;</P>

<P STYLE="margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Collegium Announces Fourth Quarter and Full
Year 2022 Preliminary Financial Results</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>-Results at or above high-end of 2022 earnings
guidance- </I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>-Final fourth quarter and full year 2022 financial
results to be announced after market closes on Thursday, February 23-</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>STOUGHTON, Mass., February 6, 2023</B> -- Collegium
Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company, today announced preliminary, unaudited financial
results for the fourth quarter and full year ended December 31, 2022.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&ldquo;2022 was a pivotal year for Collegium Pharmaceutical.
We estimate fourth quarter and full year 2022 GAAP operating expenses in the range of $38.4 million to $43.4 million and in the range
of $176.5 million to $181.5 million, respectively, and we estimate fourth quarter and full year 2022 product revenues, adjusted operating
expenses and adjusted EBITDA at or above the high-end of 2022 earnings guidance,&rdquo; said Joe Ciaffoni, President and Chief Executive
Officer of Collegium. &ldquo;We look forward to providing full year 2022 results on our fourth quarter earnings call.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Fourth Quarter and Full Year 2022 Preliminary
Results</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">For the fiscal year ended December 31, 2022, we currently estimate: </FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in">o</TD><TD>Product revenues in the range of $460.0 million to $462.5 million;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in">o</TD><TD STYLE="text-align: left">GAAP operating expenses in the range of $176.5 million to $181.5 million and adjusted operating expenses in the range of $122.0 million
to $124.5 million; and</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in">o</TD><TD>Adjusted EBITDA in the range of $261.5 million to $264.0 million.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">For the fourth quarter ended December 31, 2022, we currently estimate: </FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in">o</TD><TD>Product revenues in the range of $125.7 million to $128.2 million,</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in">o</TD><TD STYLE="text-align: left">GAAP operating expenses in the range of $38.4 million to $43.4 million and adjusted operating expenses in the range of $32.3 million
to $34.8 million, and</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in">o</TD><TD>Adjusted EBITDA in the range of $71.9 million to $74.4 million.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Preliminary 2022 Financial Results</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The preliminary, unaudited financial results included in this press
release are based on information available as of February 6, 2023 and management's initial review of operations for the fourth quarter
and year ended December 31, 2022. They remain subject to change based on management's ongoing review of the fourth-quarter and full year
results and are forward-looking statements. We assume no obligation to update these statements. The actual results remain subject to the
completion of management&rsquo;s and our audit committee&rsquo;s reviews and our other financial closing procedures, as well as the completion
of the preparation of our audited consolidated financial results for the year ended December&nbsp;31, 2022. During that process, we may
identify items that would require us to make adjustments, which may be material, to the information presented in this press release. While
we do not expect that our actual results for the year ended December 31, 2022 will vary materially from the preliminary, unaudited financial
results presented in this press release, there can be no assurance that these estimates will be realized. Actual results may be materially
different and are affected by the risk factors and uncertainties identified in this press release and in our annual and quarterly filings
with the Securities and Exchange Commission (&ldquo;SEC&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><IMG SRC="tm235588d1_ex99-1img001.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">These preliminary, unaudited results should be read in
conjunction with &ldquo;Management&rsquo;s Discussion and Analysis of Financial Condition and Results of Operations&rdquo; and our
consolidated financial statements and the related notes thereto included in our Annual Report on Form&nbsp;10-K&nbsp;for the year
ended December&nbsp;31, 2021 and our Quarterly Report on Form&nbsp;10-Q&nbsp;for the period ended September&nbsp;30, 2022, which
have been filed with the SEC. The preliminary, unaudited financial information presented herein should not be considered a
substitute for the financial information to be filed with the SEC in our Annual Report on Form&nbsp;10-K&nbsp;for the year ended
December&nbsp;31, 2022 once it becomes available.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Non-GAAP Financial Measures</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We have included information about certain non-GAAP financial measures
in this press release. We use these non-GAAP financial measures to understand, manage and evaluate our business as we believe they provide
additional information on the performance of our business. We believe that the presentation of these non-GAAP financial measures, taken
in conjunction with our results under GAAP, provide analysts, investors, lenders and other third parties insight into our view and assessment
of our ongoing operating performance. In addition, we believe that the presentation of these non-GAAP financial measures, when viewed
with our results under GAAP and the accompanying reconciliations, where applicable, provide supplementary information that may be useful
to analysts, investors, lenders, and other third parties in assessing our performance and results from period to period. We report these
non-GAAP financial measures to portray the results of our operations prior to considering certain income statement elements. These non-GAAP
financial measures should be considered in addition to, and not as a substitute for, or superior to, net income or other financial measures
calculated in accordance with GAAP.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In this press release we discuss the following financial measures that
are not calculated in accordance with GAAP.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Adjusted EBITDA</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Adjusted EBITDA is a non-GAAP financial measure that represents GAAP
net income (loss) adjusted to exclude interest expense, interest income, the benefit from or provision for income taxes, depreciation,
amortization, stock-based compensation, and other adjustments to reflect changes that occur in our business but do not represent ongoing
operations. Adjusted EBITDA, as used by us, may be calculated differently from, and therefore may not be comparable to, similarly titled
measures used by other companies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">There are several limitations related to the use of adjusted EBITDA
rather than net income (loss), which is the nearest GAAP equivalent, such as:</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">adjusted EBITDA excludes depreciation and amortization, and, although these
are non-cash expenses, the assets being depreciated or amortized may have to be replaced in the future, the cash requirements for which
are not reflected in adjusted EBITDA;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">we exclude stock-based compensation expense from adjusted EBITDA although
(a) it has been, and will continue to be for the foreseeable future, a significant recurring expense for our business and an important
part of our compensation strategy and (b) if we did not pay out a portion of our compensation in the form of stock-based compensation,
the cash salary expense included in operating expenses would be higher, which would affect our cash position;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">adjusted EBITDA does not reflect changes in, or cash requirements for, working
capital needs;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">adjusted EBITDA does not reflect the benefit from or provision for income
taxes or the cash requirements to pay taxes;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">adjusted EBITDA does not reflect historical cash expenditures or future requirements
for capital expenditures or contractual commitments;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">we exclude impairment expenses from adjusted EBITDA and, although these are
non-cash expenses, the asset being impaired may have to be replaced in the future, the cash requirements for which are not reflected in
adjusted EBITDA;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">we exclude restructuring expenses from adjusted EBITDA. Restructuring expenses
primarily include employee severance and contract termination costs that are not related to acquisitions. The amount and/or frequency
of these restructuring expenses are not part of our underlying business;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">we exclude litigation settlements from adjusted EBITDA, as well as any applicable
income items or credit adjustments due to subsequent changes in estimates. This does not include our legal fees to defend claims, which
are expensed as incurred;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0"><IMG SRC="tm235588d1_ex99-1img001.jpg" ALT="">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">we exclude acquisition related expenses as the amount and/or frequency of
these expenses are not part of our underlying business. Acquisition related expenses include transaction costs, which primarily consisted
of financial advisory, banking, legal, and regulatory fees, and other consulting fees, incurred to complete the acquisition, employee-related
expenses (severance cost and benefits) for terminated employees after the acquisition, and miscellaneous other acquisition expenses incurred;
and</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">we exclude recognition of the step-up basis in inventory from acquisitions
(i.e., the adjustment to record inventory from historic cost to fair value at acquisition) as the adjustment does not reflect the ongoing
expense associated with sale of our products as part of our underlying business.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">Because we have not yet completed our&nbsp;year-end&nbsp;closing
process and because of the forward-looking nature of the estimated adjusted EBITDA ranges presented above for the fourth quarter and year
ended December 31, 2022, we do not have specific quantifications of the amounts that would be required to provide a reconciliation of
net income (loss), the most directly comparable financial measure calculated and presented in accordance with GAAP to adjusted EBITDA
for the fourth quarter and year ended December&nbsp;31, 2022. We believe that there is a degree of variability with respect to certain
of the GAAP measures and certain adjustments made to arrive at the relevant&nbsp;non-GAAP&nbsp;measure that precludes us from providing
an accurate preliminary estimate of a GAAP to&nbsp;non-GAAP&nbsp;reconciliation without unreasonable effort or expense. As a result, we
believe that providing estimates of the amounts that would be required to reconcile the ranges of our adjusted EBITDA would imply a degree
of precision that would be confusing or misleading to investors for the reasons identified above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><I>Adjusted Operating Expenses</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">Adjusted operating expenses is a non-GAAP
financial measure that represents GAAP operating expenses adjusted to exclude stock-based compensation expense, and other adjustments
to reflect changes that occur in our business but do not represent ongoing operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Set forth below is a reconciliation of operating
expenses, the most directly comparable financial measure calculated and reported in accordance with GAAP, to adjusted operating expenses
for high and low end of the preliminary ranges set forth herein for the three months and year ended December 31, 2022. Our calculation
of adjusted operating expenses may not be comparable to the calculation of similarly titled measures presented by other companies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">Three Months Ended</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">Year Ended</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">December 31, 2022</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">December 31, 2022</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid">(in millions, unaudited)</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Low</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">High</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Low</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">High</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 48%; font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 1pt">GAAP operating expenses</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">38.4</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">43.4</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">176.5</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">181.5</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 1pt">Stock-based compensation</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">5.8</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">6.8</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">23.0</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">24.0</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 1pt">Acquisition-related expense</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">0.3</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">1.8</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">31.5</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">33.0</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt; padding-left: 1pt">Adjusted operating expenses</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">32.3</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">34.8</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">122.0</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">124.5</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Fourth Quarter and Full Year 2022 Financial Results Conference Call
Information&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Fourth quarter and full year 2022 financial results
to be announced after market closes on Thursday, February 23, 2023. Following the release of the financials, the Company will host a live
conference call and webcast at&nbsp;4:30 p.m. ET.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">To access the conference call, please dial
(877) 407-8037 (U.S.) or (201) 689-8037 (International) and reference the &ldquo;Collegium Pharmaceutical Q4 2022 Earnings
Call.&rdquo; An audio webcast will be accessible from the Investors section of the Company&rsquo;s
website:&nbsp;www.collegiumpharma.com. The webcast will be available for replay on the Company&rsquo;s website approximately two
hours after the event.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="tm235588d1_ex99-1img001.jpg" ALT=""><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>About&nbsp;Collegium Pharmaceutical, Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Collegium is a diversified, specialty pharmaceutical
company committed to improving the lives of people living with serious medical conditions. Collegium&rsquo;s headquarters are located
in&nbsp;Stoughton, Massachusetts. For more information, please visit the Company&rsquo;s website at&nbsp;www.collegiumpharma.com.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Forward-Looking Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">This press release contains forward-looking statements
within the meaning of The Private Securities Litigation Reform Act of 1995. We may, in some cases, use terms such as &quot;predicts,&quot;
 &quot;forecasts,&quot; &quot;believes,&quot; &quot;potential,&quot; &quot;proposed,&quot; &quot;continue,&quot; &quot;estimates,&quot;
 &quot;anticipates,&quot; &quot;expects,&quot; &quot;plans,&quot; &quot;intends,&quot; &quot;may,&quot; &quot;could,&quot; &quot;might,&quot;
 &quot;should&quot; or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Examples
of forward-looking statements contained in this press release include, among others, statements related to our fourth quarter and full
year 2022 preliminary financial results, including preliminary product revenue, adjusted operating expenses and adjusted EBITDA, current
and future market opportunities for our products and our assumptions related thereto, expectations (financial or otherwise) and intentions,
and other statements that are not historical facts. Such statements are subject to numerous important factors, risks and uncertainties
that may cause actual events or results, performance, or achievements to differ materially from the company's current expectations, including
risks relating to, among others: risks related to the ability to realize the anticipated benefits of our acquisitions at all or within
the expected time period; unknown liabilities; risks related to future opportunities and plans for our products, including uncertainty
of the expected financial performance of such products; the impact of the COVID-19 pandemic on our ability to conduct our business, reach
our customers, and supply the market with our products; our ability to commercialize and grow sales of our products; our ability to manage
our relationships with licensors; the success of competing products that are or become available; our ability to obtain and maintain regulatory
approval of our products and any product candidates, and any related restrictions, limitations, and/or warnings in the label of an approved
product; the size of the markets for our products and product candidates, and our ability to service those markets; our ability to obtain
reimbursement and third-party payor contracts for our products; the rate and degree of market acceptance of our products and product candidates;
the costs of commercialization activities, including marketing, sales and distribution; changing market conditions for our products; the
outcome of any patent infringement or other litigation that may be brought by or against us; the outcome of any governmental investigation
related to our business; our ability to secure adequate supplies of active pharmaceutical ingredient for each of our products and manufacture
adequate supplies of commercially saleable inventory; our ability to obtain funding for our operations and business development; regulatory
developments in the&nbsp;U.S.; our expectations regarding our ability to obtain and maintain sufficient intellectual property protection
for our products; our ability to comply with stringent&nbsp;U.S.&nbsp;and foreign government regulation in the manufacture of pharmaceutical
products, including&nbsp;U.S. Drug Enforcement Agency, or DEA, compliance; our customer concentration; and the accuracy of our estimates
regarding expenses, revenue, capital requirements and need for additional financing. These and other risks are described under the heading
 &quot;Risk Factors&quot; in our Annual Reports on Form 10-K and Quarterly Reports on Form 10-Q and other filings with the&nbsp;SEC. Any
forward-looking statements that we make in this press release speak only as of the date of this press release. We assume no obligation
to update our forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press
release.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Investor Contact:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Christopher James, M.D.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Vice President, Investor Relations</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">ir@collegiumpharma.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 4; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.2
<SEQUENCE>3
<FILENAME>tm235588d1_ex99-2.htm
<DESCRIPTION>EXHIBIT 99.2
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="text-align: right; margin: 0"><B>Exhibit 99.2</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0"><IMG SRC="tm235588d1_ex99-2img001.jpg" ALT="">&nbsp;</P>

<P STYLE="margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Collegium Pharmaceutical, Inc. Announces Proposed
Convertible Senior Notes Offering</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>STOUGHTON, Mass., February 6, 2023</B> -- Collegium
Pharmaceutical, Inc. (Nasdaq: COLL) today announced its intention to offer, subject to market and other conditions, $175,000,000 aggregate
principal amount of convertible senior notes due 2029 (the &ldquo;notes&rdquo;) in a private offering to qualified institutional buyers
pursuant to Rule 144A under the Securities Act of 1933, as amended (the &ldquo;Securities Act&rdquo;). Collegium also expects to grant
the initial purchaser of the notes an option to purchase, for settlement within a period of 13 days from, and including, the date the
notes are first issued, up to an additional $26,250,000 principal amount of notes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">The notes will be senior, unsecured obligations
of Collegium, will accrue interest payable semi-annually in arrears and will mature on February 15, 2029, unless earlier repurchased,
redeemed or converted. Noteholders will have the right to convert their notes in certain circumstances and during specified periods. Collegium
will settle conversions by paying or delivering, as applicable, cash, shares of its common stock or a combination of cash and shares of
its common stock, at Collegium&rsquo;s election.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">The notes will be redeemable, in whole or in part
(subject to certain limitations), for cash at Collegium&rsquo;s option at any time, and from time to time, on or after February 17, 2026
and on or before the 40th scheduled trading day before the maturity date, but only if the last reported sale price per share of Collegium&rsquo;s
common stock exceeds 130% of the conversion price for a specified period of time. The redemption price will be equal to the principal
amount of the notes to be redeemed, plus accrued and unpaid interest, if any, to, but excluding, the redemption date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">If certain corporate events that constitute a
 &ldquo;fundamental change&rdquo; occur, then, subject to a limited exception, noteholders may require Collegium to repurchase their notes
for cash. The repurchase price will be equal to the principal amount of the notes to be repurchased, plus accrued and unpaid interest,
if any, to, but excluding, the applicable repurchase date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The interest rate, initial conversion rate and
other terms of the notes will be determined at the pricing of the offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Collegium intends to use a portion of the net
proceeds from the offering to finance the concurrent repurchase of a portion of its 2.625% Convertible Senior Notes due 2026 (the &ldquo;2026
notes&rdquo;), as described below, and the remainder of the net proceeds for general corporate purposes, which may include working capital,
capital expenditures and implementation of Collegium's capital allocation strategy, which is focused on executing business development
transactions targeting commercial-stage, durable assets; rapid repayment of debt; and opportunistically returning capital to shareholders.
Collegium has not designated any specific uses, other than the repurchase of 2026 notes, and has no current agreements with respect to
any acquisition or strategic transaction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Contemporaneously with the pricing of the notes
in the offering, Collegium intends to enter into separate privately negotiated transactions with certain holders of the 2026 notes to
repurchase a portion of such notes on terms to be negotiated with such holders (each a &ldquo;note repurchase&rdquo; and collectively
the &ldquo;2026 notes repurchases&rdquo;). The terms of each note repurchase are anticipated to be negotiated on an individual basis and
will depend on several factors, including the market price of Collegium&rsquo;s common stock and the trading price of the 2026 notes at
the time of such note repurchase. No assurance can be given as to how much, if any, of the 2026 notes will be repurchased or the terms
on which they will be repurchased.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Collegium expects that certain holders of
2026 notes that sell their 2026 notes in negotiated transactions with Collegium may enter into or unwind various derivatives with
respect to Collegium&rsquo;s common stock and/or purchase shares of its common stock in the market. The amount of Collegium&rsquo;s
common stock that such holders purchase may be substantial in relation to the historic average daily trading volume of the common
stock. In addition, Collegium expects that certain purchasers of the notes offered in the offering of notes may establish a short
position with respect to its common stock by short selling the common stock or by entering into short derivative positions with
respect to the common stock, in each case, in connection with the offering. The net effect of the above market activities by holders
of 2026 notes and purchasers of the notes offered in the offering could increase (or reduce the size of any decrease in) or decrease
(or reduce the size of any increase in) the market price of Collegium&rsquo;s common stock, the market price of the notes offered in
the offering and/or the initial conversion price of the notes, and Collegium cannot predict the magnitude of such market activities
or the overall effect that will have on the market price of the notes, the market price of its common stock or the initial
conversion price of the notes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="tm235588d1_ex99-2img001.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">The notes will only be offered to persons reasonably
believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act. The offer and sale of the notes and any
shares of common stock issuable upon conversion of the notes have not been, and will not be, registered under the Securities Act or any
other securities laws, and the notes and any such shares cannot be offered or sold except pursuant to an exemption from, or in a transaction
not subject to, the registration requirements of the Securities Act and any other applicable securities laws. This press release does
not constitute an offer to sell, or the solicitation of an offer to buy, the notes or any shares of common stock issuable upon conversion
of the notes, nor will there be any sale of the notes or any such shares, in any state or other jurisdiction in which such offer, sale
or solicitation would be unlawful.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>About Collegium Pharmaceutical, Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Collegium is a diversified, specialty pharmaceutical
company committed to improving the lives of people living with serious medical conditions. Collegium&rsquo;s headquarters are located
in Stoughton, Massachusetts.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Forward-Looking Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">This press release includes forward-looking statements
within the meaning of The Private Securities Litigation Reform Act of 1995, including statements regarding: whether Collegium will issue
the notes; the completion, timing and size of the proposed offering; the intended use of the net proceeds from the offering; the terms
of the notes being offered; Collegium&rsquo;s expectations regarding the effects of the 2026 notes repurchases; and whether the 2026 notes
repurchases will close. Collegium may, in some cases, use terms such as &quot;predicts,&quot; &quot;forecasts,&quot; &quot;believes,&quot;
 &quot;potential,&quot; &quot;proposed,&quot; &quot;continue,&quot; &quot;estimates,&quot; &quot;anticipates,&quot; &quot;expects,&quot;
 &quot;plans,&quot; &quot;intends,&quot; &quot;may,&quot; &quot;could,&quot; &quot;might,&quot; &quot;should&quot; or other words that
convey uncertainty of future events or outcomes to identify these forward-looking statements. Forward-looking statements represent Collegium&rsquo;s
current expectations regarding future events and are subject to known and unknown risks and uncertainties that could cause actual results
to differ materially from those implied by the forward-looking statements. Among those risks and uncertainties are risks related to market
conditions, including market interest rates, the trading price and volatility of Collegium&rsquo;s common stock, and risks relating to
the proposed transactions, Collegium and its business, including those described under the heading &ldquo;Risk Factors&rdquo; in Collegium&rsquo;s
Quarterly Report on Form 10-Q for the quarter ended September 30, 2022 and other filings with the SEC, and in the preliminary offering
memorandum related to the proposed offering. Collegium may not consummate the proposed offering or the 2026 notes repurchases described
in this press release and, if the proposed transactions are consummated, cannot provide any assurances regarding the final terms of the
offer, the notes, the 2026 notes repurchases or its ability to effectively apply the net proceeds from the offering as described above.
Any forward-looking statements included in this press release speak only as of the date of this press release. Collegium does not undertake
any obligation to update the statements included in this press release for subsequent developments, whether as a result of new information,
future events or otherwise, except as may be required by law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Investor Contact:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Christopher James, M.D.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Vice President, Investor Relations</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">ir@collegiumpharma.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>4
<FILENAME>coll-20230206.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.17a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: +aA5w7xRiXgen8uLa3ZcWayHCbOdzZR+iYkxtmBzbXmKzy0vkTPqoycufobWkTML -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2021q4" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:srt-types="http://fasb.org/srt-types/2021-01-31" xmlns:coll="http://collegiumpharma.com/20230206" elementFormDefault="qualified" targetNamespace="http://collegiumpharma.com/20230206">
    <annotation>
      <appinfo>
	<link:roleType roleURI="http://collegiumpharma.com/role/Cover" id="Cover">
	  <link:definition>00000001 - Document - Cover</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:linkbaseRef xlink:type="simple" xlink:href="coll-20230206_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="coll-20230206_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2021q4" schemaLocation="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd" />
    <import namespace="http://fasb.org/us-gaap/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd" />
    <import namespace="http://fasb.org/us-types/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2021" schemaLocation="https://xbrl.sec.gov/country/2021/country-2021.xsd" />
    <import namespace="http://fasb.org/srt/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd" />
    <import namespace="http://fasb.org/srt-types/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>5
<FILENAME>coll-20230206_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.17a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>6
<FILENAME>coll-20230206_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.17a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://collegiumpharma.com/role/Cover" xlink:href="coll-20230206.xsd#Cover" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://collegiumpharma.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>tm235588d1_ex99-1img001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm235588d1_ex99-1img001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !/ . # 2(  A$! Q$!_\0
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M-'&%)^N!3-0U.#384EN7*H[A!@9Y/?Z  DGL :?>7T5E!YLI;!8*JJN69B<
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7Q$7<,,;+@#RI2X/YJ,5;HHI%)65C_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>tm235588d1_ex99-2img001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm235588d1_ex99-2img001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !/ . # 2(  A$! Q$!_\0
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M-'&%)^N!3-0U.#384EN7*H[A!@9Y/?Z  DGL :?>7T5E!YLI;!8*JJN69B<
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7Q$7<,,;+@#RI2X/YJ,5;HHI%)65C_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139950355345744">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>Feb. 06, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Feb.  06,  2023<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-37372<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">COLLEGIUM PHARMACEUTICAL, INC.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001267565<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">03-0416362<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">VA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">100 Technology Center Drive<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 300<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Stoughton<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">02072<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">781<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">713-3699<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common stock, par value $0.001 per share<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">COLL<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>tm235588d1_8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2021q4"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="coll-20230206.xsd" xlink:type="simple"/>
    <context id="From2023-02-06to2023-02-06">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001267565</identifier>
        </entity>
        <period>
            <startDate>2023-02-06</startDate>
            <endDate>2023-02-06</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <dei:EntityCentralIndexKey contextRef="From2023-02-06to2023-02-06">0001267565</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="From2023-02-06to2023-02-06">false</dei:AmendmentFlag>
    <dei:DocumentType contextRef="From2023-02-06to2023-02-06">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="From2023-02-06to2023-02-06">2023-02-06</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="From2023-02-06to2023-02-06">COLLEGIUM PHARMACEUTICAL, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="From2023-02-06to2023-02-06">VA</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="From2023-02-06to2023-02-06">001-37372</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="From2023-02-06to2023-02-06">03-0416362</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="From2023-02-06to2023-02-06">100 Technology Center Drive</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="From2023-02-06to2023-02-06">Suite 300</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="From2023-02-06to2023-02-06">Stoughton</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="From2023-02-06to2023-02-06">MA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="From2023-02-06to2023-02-06">02072</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="From2023-02-06to2023-02-06">781</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="From2023-02-06to2023-02-06">713-3699</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="From2023-02-06to2023-02-06">Common stock, par value $0.001 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="From2023-02-06to2023-02-06">COLL</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="From2023-02-06to2023-02-06">NASDAQ</dei:SecurityExchangeName>
    <dei:WrittenCommunications contextRef="From2023-02-06to2023-02-06">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="From2023-02-06to2023-02-06">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="From2023-02-06to2023-02-06">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="From2023-02-06to2023-02-06">false</dei:PreCommencementIssuerTenderOffer>
    <dei:EntityEmergingGrowthCompany contextRef="From2023-02-06to2023-02-06">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>11
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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M 0  &@   'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QSM9$]#H,P#(6O$N4
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M4')O<',O87!P+GAM;%!+ 0(4 Q0    ( -J!1E8*C^D][P   "L"   1
M          "  :\   !D;V-0<F]P<R]C;W)E+GAM;%!+ 0(4 Q0    ( -J!
M1E:97)PC$ 8  )PG   3              "  <T!  !X;"]T:&5M92]T:&5M
M93$N>&UL4$L! A0#%     @ VH%&5AYP9<IN!   ,1$  !@
M ("!#@@  'AL+W=O<FMS:&5E=',O<VAE970Q+GAM;%!+ 0(4 Q0    ( -J!
M1E:?H!OPL0(  .(,   -              "  ;(,  !X;"]S='EL97,N>&UL
M4$L! A0#%     @ VH%&5I>*NQS     $P(   L              ( !C@\
M %]R96QS+RYR96QS4$L! A0#%     @ VH%&5JK$(A8S 0  (@(   \
M         ( !=Q   'AL+W=O<FMB;V]K+GAM;%!+ 0(4 Q0    ( -J!1E8D
M'INBK0   /@!   :              "  =<1  !X;"]?<F5L<R]W;W)K8F]O
M:RYX;6PN<F5L<U!+ 0(4 Q0    ( -J!1E9ED'F2&0$  ,\#   3
M      "  ;P2  !;0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@     )  D /@(
'  84      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.4</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>23</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>3</UnitCount>
  <MyReports>
    <Report instance="tm235588d1_8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://collegiumpharma.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="tm235588d1_8k.htm">tm235588d1_8k.htm</File>
    <File>coll-20230206.xsd</File>
    <File>coll-20230206_lab.xml</File>
    <File>coll-20230206_pre.xml</File>
    <File>tm235588d1_ex99-1.htm</File>
    <File>tm235588d1_ex99-2.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="23">http://xbrl.sec.gov/dei/2021q4</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>16
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "tm235588d1_8k.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2021q4": 23
   },
   "contextCount": 1,
   "dts": {
    "inline": {
     "local": [
      "tm235588d1_8k.htm"
     ]
    },
    "labelLink": {
     "local": [
      "coll-20230206_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "coll-20230206_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "coll-20230206.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd",
      "https://xbrl.sec.gov/country/2021/country-2021.xsd",
      "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd"
     ]
    }
   },
   "elementCount": 59,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2021q4": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 23,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "coll",
   "nsuri": "http://collegiumpharma.com/20230206",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "baseRef": "tm235588d1_8k.htm",
      "contextRef": "From2023-02-06to2023-02-06",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "00000001 - Document - Cover",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://collegiumpharma.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "baseRef": "tm235588d1_8k.htm",
      "contextRef": "From2023-02-06to2023-02-06",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of changes contained within amended document.",
        "label": "Amendment Description"
       }
      }
     },
     "localname": "AmendmentDescription",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://collegiumpharma.com/role/Cover"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://collegiumpharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AnnualInformationForm": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.",
        "label": "Annual Information Form"
       }
      }
     },
     "localname": "AnnualInformationForm",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://collegiumpharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditedAnnualFinancialStatements": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.",
        "label": "Audited Annual Financial Statements"
       }
      }
     },
     "localname": "AuditedAnnualFinancialStatements",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://collegiumpharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://collegiumpharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CountryRegion": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Region code of country",
        "label": "Country Region"
       }
      }
     },
     "localname": "CountryRegion",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://collegiumpharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://collegiumpharma.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAccountingStandard": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.",
        "label": "Document Accounting Standard"
       }
      }
     },
     "localname": "DocumentAccountingStandard",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://collegiumpharma.com/role/Cover"
     ],
     "xbrltype": "accountingStandardItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r11",
      "r13",
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://collegiumpharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://collegiumpharma.com/role/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://collegiumpharma.com/role/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://collegiumpharma.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentPeriodStartDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.",
        "label": "Document Period Start Date"
       }
      }
     },
     "localname": "DocumentPeriodStartDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://collegiumpharma.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r12"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://collegiumpharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentRegistrationStatement": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a registration statement.",
        "label": "Document Registration Statement"
       }
      }
     },
     "localname": "DocumentRegistrationStatement",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://collegiumpharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentShellCompanyEventDate": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date of event requiring a shell company report.",
        "label": "Document Shell Company Event Date"
       }
      }
     },
     "localname": "DocumentShellCompanyEventDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://collegiumpharma.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentShellCompanyReport": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.",
        "label": "Document Shell Company Report"
       }
      }
     },
     "localname": "DocumentShellCompanyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://collegiumpharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://collegiumpharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://collegiumpharma.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated by Reference [Text Block]"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://collegiumpharma.com/role/Cover"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://collegiumpharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://collegiumpharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine3": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 3 such as an Office Park",
        "label": "Entity Address, Address Line Three"
       }
      }
     },
     "localname": "EntityAddressAddressLine3",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://collegiumpharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://collegiumpharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCountry": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ISO 3166-1 alpha-2 country code.",
        "label": "Entity Address, Country"
       }
      }
     },
     "localname": "EntityAddressCountry",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://collegiumpharma.com/role/Cover"
     ],
     "xbrltype": "countryCodeItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://collegiumpharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://collegiumpharma.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not.  Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.",
        "label": "Entity Bankruptcy Proceedings, Reporting Current"
       }
      }
     },
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://collegiumpharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://collegiumpharma.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://collegiumpharma.com/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://collegiumpharma.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://collegiumpharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r19"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Elected Not To Use the Extended Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://collegiumpharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://collegiumpharma.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://collegiumpharma.com/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://collegiumpharma.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://collegiumpharma.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPrimarySicNumber": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.",
        "label": "Entity Primary SIC Number"
       }
      }
     },
     "localname": "EntityPrimarySicNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://collegiumpharma.com/role/Cover"
     ],
     "xbrltype": "sicNumberItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://collegiumpharma.com/role/Cover"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://collegiumpharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://collegiumpharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://collegiumpharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://collegiumpharma.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://collegiumpharma.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r17"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://collegiumpharma.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_Extension": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Extension number for local phone number.",
        "label": "Extension"
       }
      }
     },
     "localname": "Extension",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://collegiumpharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://collegiumpharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_NoTradingSymbolFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a security having no trading symbol.",
        "label": "No Trading Symbol Flag"
       }
      }
     },
     "localname": "NoTradingSymbolFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://collegiumpharma.com/role/Cover"
     ],
     "xbrltype": "trueItemType"
    },
    "dei_OtherReportingStandardItemNumber": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.",
        "label": "Other Reporting Standard Item Number"
       }
      }
     },
     "localname": "OtherReportingStandardItemNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://collegiumpharma.com/role/Cover"
     ],
     "xbrltype": "otherReportingStandardItemNumberItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r7"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://collegiumpharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r8"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://collegiumpharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://collegiumpharma.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_Security12gTitle": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(g) registered security.",
        "label": "Title of 12(g) Security"
       }
      }
     },
     "localname": "Security12gTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://collegiumpharma.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://collegiumpharma.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SecurityReportingObligation": {
     "auth_ref": [
      "r9"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.",
        "label": "Security Reporting Obligation"
       }
      }
     },
     "localname": "SecurityReportingObligation",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://collegiumpharma.com/role/Cover"
     ],
     "xbrltype": "securityReportingObligationItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r10"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://collegiumpharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://collegiumpharma.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://collegiumpharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 3
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r10": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r11": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r12": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r13": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r14": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r15": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r16": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r17": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r18": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r19": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r5": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "g",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r6": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12, 13, 15d",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r7": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r8": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r9": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "15",
   "Subsection": "d",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>17
<FILENAME>0001104659-23-011184-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001104659-23-011184-xbrl.zip
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M6>F%F*^"-S1'\4?%OHEL;HVZDVKJY1]02P,$%     @ VH%&5O?]@G?_"@
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M04/E^OL-_*WGMUG2)+JD',-781H:QZOXM>T9"_CM!0%1T'8%+=N7"U&N],;
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MRH$."X8QP>W%T\5S3<66D<9L(J;"8LU6O7T:79G5P4MTV5A\/C8+^&NJZU2
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M-POC3J[4K4A7<\>\^_&M,Z!_S0M[YJAPWFT=??W4__SQH\>2_P=02P,$%
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M[Q4^P)&+K]1K^$[[Y8O6\])+[8-V_DE# ,6!CQ+@JP"8 @>9/ CZ<1SYJ9?
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M'<?8RB9S$]$)?6T\,$ R5%%JW-Y8 :%%1++6IS/Y&^_CB0HA'BH9A+IPB$4
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M/B;*J.-ZC?!2-!U5CFT'E,OL'H-17O'RFV4$5_\?^[+T##CXAXSVR632\AR
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MF9MC! /@$I!,.,H@CB94L\7,%FV9>WE$_;$8%F82(-]0CPU/'&B(, PP/",
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MH<S0Y-GKZ_/?L5KHL[?==U<G_P]02P,$%     @ VH%&5A&'7;[B#@  3#8
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M_C68_^=A]*_(_@]02P$"% ,4    " #:@496I:)*M#\#   *#   $0
M        @ $     8V]L;"TR,#(S,#(P-BYX<V102P$"% ,4    " #:@496
M]_V"=_\*  !LAP  %0              @ %N P  8V]L;"TR,#(S,#(P-E]L
M86(N>&UL4$L! A0#%     @ VH%&5@^WK-A9!P  SU@  !4
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64$L%!@     &  8 B@$  #Y4      $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
